<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854785</url>
  </required_header>
  <id_info>
    <org_study_id>177/2020</org_study_id>
    <nct_id>NCT04854785</nct_id>
  </id_info>
  <brief_title>Neuroinflammation in COVID-19 and Depression</brief_title>
  <official_title>Imaging Neuroinflammation in COVID-19 and Persistent Depression With/Without Other Neuropsychiatric Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use state of the art brain imaging technology to investigate&#xD;
      neuroinflammation in participants with depression after the respiratory symptoms of COVID-19&#xD;
      have passed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will undergo two PET scans: one [11C]SL25.1188 scan (for TSPO) and one&#xD;
      [11C]SL25.1188 scan (for MAO-B) - as well as one MRI scan.&#xD;
&#xD;
      The primary hypotheses are:&#xD;
&#xD;
        1. TSPO VT and MAO-B VT are greater in the PFC, ACC, and hippocampus in COVID-19 with new&#xD;
           onset, persistent MDE with or without other neuropsychiatric symptoms after recovery&#xD;
           from mild respiratory symptoms (DNP-mild).&#xD;
&#xD;
        2. TSPO VT and MAO-B VT are greater in the PFC, ACC, and hippocampus in COVID-19 with new&#xD;
           onset, persistent MDE with or without other persistent neuropsychiatric symptoms after&#xD;
           recovery from moderate respiratory symptoms (DNP-moderate).&#xD;
&#xD;
      Exploratory hypotheses are:&#xD;
&#xD;
        1. Greater TSPO VT and MAO-B VT in the PFC, ACC, and hippocampus will be positively&#xD;
           associated with severity of MDE symptoms and poorer performance on cognitive tasks.&#xD;
&#xD;
        2. TSPO VT and MAO-B VT will be positively correlated in the PFC, ACC and hippocampus in&#xD;
           COVID-DNP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TSPO VT in prefrontal cortex, anterior cingulate cortex, and hippocampus</measure>
    <time_frame>within 3 to 4 weeks after initiation of screening</time_frame>
    <description>PET scan measures in DNP-mild and DNP-moderate compared to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAO-B VT in prefrontal cortex, anterior cingulate cortex, and hippocampus</measure>
    <time_frame>within 3 to 4 weeks after initiation of screening</time_frame>
    <description>PET scan measures in DNP-mild and DNP-moderate compared to healthy controls</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Major Depressive Episode</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group 1 (DNP-mild)</arm_group_label>
    <description>Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (DNP-moderate)</arm_group_label>
    <description>Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (Healthy Control Participants)</arm_group_label>
    <description>Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[18F]FEPPA PET scan</intervention_name>
    <description>One [18F]FEPPA PET for translocator protein (TSPO) VT and one MRI scan</description>
    <arm_group_label>Group 1 (DNP-mild)</arm_group_label>
    <arm_group_label>Group 2 (DNP-moderate)</arm_group_label>
    <arm_group_label>Group 3 (Healthy Control Participants)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]SL25.1188 PET scan</intervention_name>
    <description>One [11C]SL25.1188 PET scan for monoamine oxidase B (MAO-B) VT and one MRI scan</description>
    <arm_group_label>Group 1 (DNP-mild)</arm_group_label>
    <arm_group_label>Group 2 (DNP-moderate)</arm_group_label>
    <arm_group_label>Group 3 (Healthy Control Participants)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      brain scan; also saliva, whole blood, plasma and serum samples will be kept for analysis of&#xD;
      genotype, peripheral inflammatory markers and protein binding in relation to brain scan&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and&#xD;
        have a new onset major depressive episode (MDE).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80&#xD;
&#xD;
          -  Diagnosis of COVID-19&#xD;
&#xD;
          -  Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of&#xD;
             pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of&#xD;
             pneumonia but not severe enough to require ongoing use of supplementary oxygen.&#xD;
&#xD;
          -  Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever,&#xD;
             chills, or gastrointestinal upset for at least 4 weeks&#xD;
&#xD;
          -  New onset major depressive episode (MDE) within 3 months after COVID-19, as verified&#xD;
             by the Research Version of Structured Clinical Interview for DSM 5)&#xD;
&#xD;
          -  High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971&#xD;
             polymorphism, based on saliva genetic testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime history of an autoimmune disease&#xD;
&#xD;
          -  Lifetime history of a neurological disease, excluding migraine&#xD;
&#xD;
          -  Lifetime diagnosis of Antisocial or Borderline Personality disorder&#xD;
&#xD;
          -  Lifetime history of psychotic symptoms prior to COVID-19&#xD;
&#xD;
          -  Lifetime diagnosis of Substance of Alcohol Use Disorder&#xD;
&#xD;
          -  Use of street drugs, including marijuana, in the past two months&#xD;
&#xD;
          -  Presence of cigarette smoking in the past two months&#xD;
&#xD;
          -  Positive urine drug or cotinine screen at any timepoint during the study&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Currently breastfeeding&#xD;
&#xD;
          -  Use of aspirin or ibuprofen within the past 2 weeks&#xD;
&#xD;
          -  Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4&#xD;
             weeks&#xD;
&#xD;
          -  Use of herbal remedies in the past month&#xD;
&#xD;
          -  Presence of metal implant, object or electrical devices that are contraindicated for&#xD;
             MRI&#xD;
&#xD;
          -  Current disorders of coagulation, blood or ongoing use of anticoagulant medication&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Weight over 400lbs and height over 7ft&#xD;
&#xD;
          -  History of undergoing a number of PET scans that will lead participants to exceed the&#xD;
             annual (20mSv) / lifetime (8 PET scans) radiation by completing this study&#xD;
&#xD;
          -  Current participation in another research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey H Meyer, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain Health Imaging Centre, Centre for Addiction and Mental Health (CAMH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joeffre Braga</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>30741</phone_ext>
    <email>joeffre.braga@camh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H Meyer, M.D., PhD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>34007</phone_ext>
      <email>jeffrey.meyer@utoronto.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Jeff Meyer</investigator_full_name>
    <investigator_title>Program Head, Neurochemical Imaging for Mood Disorders</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

